Genetics of Parkinson's disease and parkinsonism

Expert Review of Neurotherapeutics

Volumn 7, Issue 6, 2007, Pages 657-666

  Douglas, Michael R ^a   Lewthwaite, Alistair J ^a   Nicholl, David J ^b  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

synuclein; LRRK2; Neurogenetics; PARK loci; Parkin; Parkinson's disease; PINK1

Indexed keywords

ALPHA SYNUCLEIN; DJ 1 PROTEIN; LEUCINE RICH REPEAT KINASE 2; PARK10 PROTEIN; PARK12 PROTEIN; PARK13 PROTEIN; PARK9 PROTEIN; PARKIN; PHOSPHATASE AND TENSIN HOMOLOGUE DELETED ON CHROMOSOME 10 INDUCED KINASE 1; PROTEIN SERINE THREONINE KINASE; UNCLASSIFIED DRUG;

AUTOSOMAL DOMINANT INHERITANCE; CLINICAL PRACTICE; GENE LOCUS; PARKINSON DISEASE; PARKINSONISM; RECESSIVE INHERITANCE; REVIEW;

ALPHA-SYNUCLEIN; BRAIN; CLINICAL TRIALS; GENE THERAPY; GENES, DOMINANT; GENES, RECESSIVE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; ONCOGENE PROTEINS; PARKINSON DISEASE; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; UBIQUITIN-PROTEIN LIGASES;

EID: 34250355956     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.7.6.657     Document Type: Review

References (135)

1. Samii A, Nutt JG, Ransom BR. Parkinson's disease. Lancet 363(9423), 1783-1793 (2004).
2. Gowers WR. A Manual of the Diseases of the Nervous System. Blakiston, PA, USA (1902).
3. Payami H, Larsen K, Bernard S, Nutt J. Increased risk of Parkinson's disease in parents and siblings of patients. Ann. Neurol. 36(4), 659-661 (1994).
4. Autere JM, Moilanen JS, Myllyla VV, Majamaa K. Familial aggregation of Parkinson's disease in a Finnish population. J. Neurol. Neurosurg. Psychiatry 69(1), 107-109 (2000).
5. Sveinbjornsdottir S, Hicks AA, Jonsson T et al. Familial aggregation of Parkinson's disease in Iceland. N. Engl. J. Med. 343(24), 1765-1770 (2000).
6. Preux PM, Condet A, Anglade C et al. Parkinson's disease and environmental factors. Matched case-control study in the Limousin region, France. Neuroepidemiology 19(6), 333-337 (2000).
7. Rocca WA, McDonnell SK, Strain KJ et al. Familial aggregation of Parkinson's disease: the Mayo Clinic family study. Ann. Neurol. 56(4), 495-502 (2004).
8. Trojanowski JQ, Lee VM. Parkinson's disease and related α-synucleinopathies are brain amyloidoses. Ann. NY Acad. Sci. 991, 107-110 (2003).
9. Valente EM, Abou-Sleiman PM, Caputo V et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304(5674), 1158-1160 (2004).
10. Polymeropoulos MH, Lavedan C, Leroy E et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276(5321), 2045-2047 (1997).
11. Kitada T, Asakawa S, Hattori N et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392(6676), 605-608 (1998).
12. Bonifati V, Rizzu P, van Baren MJ et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299(5604), 256-259 (2003).
13. Paisan-Ruiz C, Jain S, Evans EW et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44(4), 595-600 (2004).
14. Zimprich A, Biskup S, Leitner P et al. Mutations in LRRK2 cause autosomaldominant parkinsonism with pleomorphic pathology. Neuron 44(4), 601-607 (2004).
15. Le WD, Xu P, Jankovic J et al. Mutation in NR4A2 associated with familial Parkinson disease. Nat. Genet. 33(1), 85-89 (2003).
16. Marx FP, Holzmann C, Strauss KM et al. Identification and functional characterization of a novel R621C mutation in the synphilin-1 gene in Parkinson's disease. Hum. Mol. Genet. 12(11), 1223-1231 (2003).
17. Carr J, de la Fuente-Fernandez R, Schulzer M et al. Familial and sporadic Parkinson's disease usually display the same clinical features. Parkinsonism Relat. Disord. 9(4), 201-204 (2003).
18. Golbe LI, Di Iorio G, Sanges G et al. Clinical genetic analysis of Parkinson's disease in the Contursi kindred. Ann. Neurol. 40(5), 767-775 (1996).
19. Papapetropoulos S, Paschalis C, Athanassiadou A et al. Clinical phenotype in patients with α-synuclein Parkinson's disease living in Greece in comparison with patients with sporadic Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 70(5), 662-665 (2001).
20. Kruger R, Kuhn W, Muller T et al. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat. Genet. 18(2), 106-108 (1998).
21. Zarranz JJ, Alegre J, Gomez-Esteban JC et al. The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55(2), 164-173 (2004).
22. Vaughan J, Durr A, Tassin J et al. The α-synuclein Ala53Thr mutation is not a common cause of familial Parkinson's disease: a study of 230 European cases. European Consortium on Genetic Susceptibility in Parkinson's Disease. Ann. Neurol. 44(2), 270-273 (1998).
23. Farrer M, Maraganore DM, Lockhart P et al. α-synuclein gene haplotypes are associated with Parkinson's disease. Hum. Mol. Genet. 10(17), 1847-1851 (2001).
24. Pals P, Lincoln S, Manning J et al. α-synuclein promoter confers susceptibility to Parkinson's disease. Ann. Neurol. 56(4), 591-595 (2004).
25. Chartier-Harlin MC, Kachergus J, Roumier C et al. α-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364(9440), 1167-1169 (2004).
26. Ibanez P, Bonnet AM, Debarges B et al. Causal relation between α-synuclein gene duplication and familial Parkinson's disease. Lancet 364(9440), 1169-1171 (2004).
27. Muenter MD, Forno LS, Hornykiewicz O et al. Hereditary form of parkinsonism - dementia. Ann. Neurol. 43(6), 768-781 (1998).
28. Tan EK, Chai A, Teo YY et al. α-synuclein haplotypes implicated in risk of Parkinson's disease. Neurology 62(1), 128-131 (2004).
29. Singleton AB, Farrer M, Johnson J et al. α-synuclein locus triplication causes Parkinson's disease. Science 302(5646), 841 (2003).
30. Farrer M, Kachergus J, Forno L et al. Comparison of kindreds with parkinsonism and α-synuclein genomic multiplications. Ann. Neurol. 55(2), 174-179 (2004).
31. Maraganore DM, de Andrade M, Elbaz A et al. Collaborative analysis of α-synuclein gene promoter variability and Parkinson disease. JAMA 296(6), 661-670 (2006).
32. Spillantini MG, Schmidt ML, Lee VM et al. α-synuclein in Lewy bodies. Nature 388(6645), 839-840 (1997).
33. Spillantini MG, Goedert M. The α-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Ann. NY Acad. Sci. 920, 16-27 (2000).
34. Lee VM, Trojanowski JQ. Mechanisms of Parkinson's disease linked to pathological α-synuclein: new targets for drug discovery. Neuron 52(1), 33-38 (2006).
35. Nuscher B, Kamp F, Mehnert T et al. α-synuclein has a high affinity for packing defects in a bilayer membrane: a thermodynamics study. J. Biol. Chem. 279(21), 21966-21975 (2004).
36. Chandra S, Gallardo G, Fernandez-Chacon R, Schluter OM, Sudhof TC. α-synuclein cooperates with CSPα in preventing neurodegeneration. Cell 123(3), 383-396 (2005).
37. Chen Q, Thorpe J, Keller JN. α-synuclein alters proteasome function, protein synthesis, and stationary phase viability. J. Biol. Chem. 280(34), 30009-30017 (2005).
38. Gasser T, Muller-Myhsok B, Wszolek ZK et al. A susceptibility locus for Parkinson's disease maps to chromosome 2p13. Nat. Genet. 18(3), 262-265 (1998).
39. Pankratz N, Uniacke SK, Halter CA et al. Genes influencing Parkinson disease onset: replication of PARK3 and identification of novel loci. Neurology 62(9), 1616-1618 (2004).
40. DeStefano AL, Golbe LI, Mark MH et al. Genome-wide scan for Parkinson's disease: the GenePD Study. Neurology 57(6), 1124-1126 (2001).
41. Martinez M, Brice A, Vaughan JR et al. Genome-wide scan linkage analysis for Parkinson's disease: the European genetic study of Parkinson's disease. J. Med. Genet. 41(12), 900-907 (2004).
42. West AB, Zimprich A, Lockhart PJ et al. Refinement of the PARK3 locus on chromosome 2p13 and the analysis of 14 candidate genes. Eur. J. Hum. Genet. 9(9), 659-666 (2001).
43. Sharma M, Mueller JC, Zimprich A et al. The sepiapterin reductase gene region reveals association in the PARK3 locus: analysis of familial and sporadic Parkinson's disease in European populations. J. Med. Genet. 43(7), 557-562 (2006).
44. Leroy E, Boyer R, Auburger G et al. The ubiquitin pathway in Parkinson's disease. Nature 395(6701), 451-452 (1998).
45. Maraganore DM, Farrer MJ, Hardy JA et al. Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease. Neurology 53(8), 1858-1860 (1999).
46. Maraganore DM, Lesnick TG, Elbaz A et al. UCHL1 is a Parkinson's disease susceptibility gene. Ann. Neurol. 55(4), 512-521 (2004).
47. Meray RK, Lansbury PT Jr. Reversible monoubiquitination regulates the Parkinson's disease-associated ubiquitin hydrolase UCH-L1. J. Biol. Chem. 282(14), 10567-10575 (2007).
48. Zimprich A, Muller-Myhsok B, Farrer M et al. The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. Am. J. Hum. Genet. 74(1), 11-19 (2004).
49. Hasegawa K, Kowa H. Autosomal dominant familial Parkinson disease: older onset of age, and good response to levodopa therapy. Eur. Neurol. 38(Suppl. 1), 39-43 (1997).
50. Wszolek ZK, Pfeiffer RF, Tsuboi Y et al. Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology 62(9), 1619-1622 (2004).
51. Khan NL, Jain S, Lynch JM et al. Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain 128(Pt 12), 2786-2796 (2005).
52. Di Fonzo A, Tassorelli C, De Mari M et al. Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease. Eur. J. Hum. Genet. 14(3), 322-331 (2006).
53. Kachergus J, Mata IF, Hulihan M et al. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am. J. Hum. Genet. 76(4), 672-680 (2005).
54. Nichols WC, Pankratz N, Hernandez D et al. Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet 365(9457), 410-412 (2005).
55. Bras JM, Guerreiro RJ, Ribeiro MH et al. G2019S dardarin substitution is a common cause of Parkinson's disease in a Portuguese cohort. Mov. Disord. 20(12), 1653-1655 (2005).
56. Saunders-Pullman R, Lipton RB, Senthil G et al. Increased frequency of the LRRK2 G2019S mutation in an elderly Ashkenazi Jewish population is not associated with dementia. Neurosci. Lett. 402(1-2), 92-96 (2006).
57. Lesage S, Ibanez P, Lohmann E et al. G2019S LRRK2 mutation in French and North African families with Parkinson's disease. Ann. Neurol. 58(5), 784-787 (2005).
58. Kay DM, Kramer P, Higgins D, Zabetian CP, Payami H. Escaping Parkinson's disease: a neurologically healthy octogenarian with the LRRK2 G2019S mutation. Mov. Disord. 20(8), 1077-1078 (2005).
59. Pankratz N, Pauciulo MW, Elsaesser VE et al. Mutations in LRRK2 other than G2019S are rare in a north American-based sample of familial Parkinson's disease. Mov. Disord. 21(12), 2257-2260 (2006).
60. Funayama M, Li Y, Tomiyama H et al. Leucine-rich repeat kinase 2 G2385R variant is a risk factor for Parkinson disease in Asian population. Neuroreport 18(3), 273-275 (2007).
61. Fung HC, Chen CM, Hardy J, Singleton AB, Wu YR. A common genetic factor for Parkinson disease in ethnic Chinese population in Taiwan. BMC Neurol. 6, 47 (2006).
62. Macleod D, Dowman J, Hammond R et al. The familial parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 52(4), 587-593 (2006).
63. Pankratz N, Nichols WC, Uniacke SK et al. Significant linkage of Parkinson disease to chromosome 2q36-37. Am. J. Hum. Genet. 72(4), 1053-1057 (2003).
64. Prestel J, Sharma M, Leitner P et al. PARK11 is not linked with Parkinson's disease in European families. Eur. J. Hum. Genet. 13(2), 193-197 (2005).
65. Fung HC, Scholz S, Matarin M et al. Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol. 5(11), 911-916 (2006).
66. Elbaz A, Nelson LM, Payami H et al. Lack of replication of thirteen single-nucleotide polymorphisms implicated in Parkinson's disease: a large-scale international study. Lancet Neurol. 5(11), 917-923 (2006).
67. Periquet M, Latouche M, Lohmann E et al. Parkin mutations are frequent in patients with isolated early-onset parkinsonism. Brain 126(Pt 6), 1271-1278 (2003).
68. Lohmann E, Periquet M, Bonifati V et al. How much phenotypic variation can be attributed to parkin genotype? Ann. Neurol. 54(2), 176-185 (2003).
69. Khan NL, Graham E, Critchley P et al. Parkin disease: a phenotypic study of a large case series. Brain 126(Pt 6), 1279-1292 (2003).
70. Yamamura Y, Hattori N, Matsumine H, Kuzuhara S, Mizuno Y. Autosomal recessive early-onset parkinsonism with diurnal fluctuation: clinicopathologic characteristics and molecular genetic identification. Brain Dev. 22(Suppl. 1) S87-S91 (2000).
71. Farrer M, Chan P, Chen R et al. Lewy bodies and parkinsonism in families with parkin mutations. Ann. Neurol. 50(3), 293-300 (2001).
72. Mori H, Kondo T, Yokochi M et al. Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q. Neurology 51(3), 890-892 (1998).
73. Lucking CB, Durr A, Bonifati V et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. N. Engl. J. Med. 342(21), 1560-1567 (2000).
74. Foroud T, Uniacke SK, Liu L et al. Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease. Neurology 60(5), 796-801 (2003).
75. Hedrich K, Kann M, Lanthaler AJ et al. The importance of gene dosage studies: mutational analysis of the parkin gene in early-onset parkinsonism. Hum. Mol. Genet. 10(16), 1649-1656 (2001).
76. Hedrich K, Eskelson C, Wilmot B et al. Distribution, type, and origin of Parkin mutations: review and case studies. Mov. Disord. 19(10), 1146-1157 (2004).
77. Shimura H, Hattori N, Kubo S et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet. 25(3), 302-305 (2000).
78. Upadhya SC, Hegde AN. A potential proteasome-interacting motif within the ubiquitin-like domain of parkin and other proteins. Trends Biochem. Sci. 28(6), 280-283 (2003).
79. Moore DJ. Parkin: a multifaceted ubiquitin ligase. Biochem. Soc. Trans. 34(Pt 5), 749-753 (2006).
80. Yang Y, Nishimura I, Imai Y, Takahashi R, Lu B. Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila. Neuron 37(6), 911-924 (2003).
81. Smith WW, Pei Z, Jiang H et al. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc. Natl Acad. Sci. USA 102(51), 18676-18681 (2005).
82. Moore DJ, Zhang L, Troncoso J et al. Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress. Hum. Mol. Genet. 14(1), 71-84 (2005).
83. Valente EM, Bentivoglio AR, Dixon PH et al. Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36. Am. J. Hum. Genet. 68(4), 895-900 (2001).
84. Valente EM, Brancati F, Ferraris A et al. PARK6-linked parkinsonism occurs in several European families. Ann. Neurol. 51(1), 14-18 (2002).
85. Valente EM, Salvi S, Ialongo T et al. PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann. Neurol. 56(3), 336-341 (2004).
86. Rohe CF, Montagna P, Breedveld G et al. Homozygous PINK1 C-terminus mutation causing early-onset parkinsonism. Ann. Neurol. 56(3), 427-431 (2004).
87. Hatano Y, Li Y, Sato K et al. Novel PINK1 mutations in early-onset parkinsonism. Ann. Neurol. 56(3), 424-427 (2004).
88. Healy DG, Abou-Sleiman PM, Gibson JM et al. PINK1 (PARK6) associated Parkinson disease in Ireland. Neurology 63(8), 1486-1488 (2004).
89. Hedrich K, Hagenah J, Djarmati A et al. Clinical spectrum of homozygous and heterozygous PINK1 mutations in a large German family with Parkinson disease: role of a single hit? Arch. Neurol. 63(6), 833-838 (2006).
90. Abou-Sleiman PM, Muqit MM, McDonald NQ et al. A heterozygous effect for PINK1 mutations in Parkinson's disease? Ann. Neurol. 60(4), 414-419 (2006).
91. Toft M, Myhre R, Pielsticker L et al. PINK1 mutation heterozygosity and the risk of Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 78(1), 82-84 (2007).
92. Khan NL, Valente EM, Bentivoglio AR et al. Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study. Ann. Neurol. 52(6), 849-853 (2002).
93. Ibanez P, Lesage S, Lohmann E et al. Mutational analysis of the PINK1 gene in early-onset parkinsonism in Europe and North Africa. Brain 129(Pt 3), 686-694 (2006).
94. Hatano Y, Sato K, Elibol B et al. PARK6-linked autosomal recessive early-onset parkinsonism in Asian populations. Neurology 63(8), 1482-1485 (2004).
95. Gandhi S, Muqit MM, Stanyer L et al. PINK1 protein in normal human brain and Parkinson's disease. Brain 129(Pt 7), 1720-1731 (2006).
96. Clark IE, Dodson MW, Jiang C et al. Drosophila PINK1 is required for mitochondrial function and interacts genetically with parkin. Nature 441(7097), 1162-1166 (2006).
97. Yang Y, Gehrke S, Imai Y et al. Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila PINK1 is rescued by Parkin. Proc. Natl Acad. Sci. USA 103(28), 10793-10798 (2006).
98. Park J, Lee SB, Lee S et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 441(7097), 1157-1161 (2006).
99. Hague S, Rogaeva E, Hernandez D et al. Early-onset Parkinson's disease caused by a compound heterozygous DJ-1 mutation. Ann. Neurol. 54(2), 271-274 (2003).
100. Abou-Sleiman PM, Healy DG, Quinn N, Lees AJ, Wood NW. The role of pathogenic DJ-1 mutations in Parkinson's disease. Ann. Neurol. 54(3), 283-286 (2003).
101. Hedrich K, Djarmati A, Schafer N et al. DJ-1 (PARK7) mutations are less frequent than Parkin (PARK2) mutations in earlyonset Parkinson disease. Neurology 62(3), 389-394 (2004).
102. Dekker M, Bonifati V, van Swieten J et al. Clinical features and neuroimaging of PARK7-linked parkinsonism. Mov. Disord. 18(7), 751-757 (2003).
103. Lev N, Roncevich D, Ickowicz D, Melamed E, Offen D. Role of DJ-1 in Parkinson's disease. J. Mol. Neurosci. 29(3), 215-225 (2006).
104. Canet-Aviles RM, Wilson MA, Miller DW et al. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc. Natl Acad. Sci. USA 101(24), 9103-9108 (2004).
105. Kim RH, Smith PD, Aleyasin H et al. Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. Proc. Natl Acad. Sci. USA 102(14), 5215-5220 (2005).
106. Najim al-Din AS, Wriekat A, Mubaidin A, Dasouki M, Hiari M. Pallido-pyramidal degeneration, supranuclear upgaze paresis and dementia: Kufor-Rakeb syndrome. Acta Neurol. Scand. 89(5), 347-352 (1994).
107. Hampshire DJ, Roberts E, Crow Y et al. Kufor-Rakeb syndrome, pallido-pyramidal degeneration with supranuclear upgaze paresis and dementia, maps to 1p36. J. Med. Genet. 38(10), 680-682 (2001).
108. Williams DR, Hadeed A, al-Din AS, Wreikat AL, Lees AJ. Kufor Rakeb disease: autosomal recessive, levodopa-responsive parkinsonism with pyramidal degeneration, supranuclear gaze palsy, and dementia. Mov. Disord. 20(10), 1264-1271 (2005).
109. Ramirez A, Heimbach A, Grundemann J et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat. Genet. 38(10), 1184-1191 (2006).
110. Hicks AA, Petursson H, Jonsson T et al. A susceptibility gene for late-onset idiopathic Parkinson's disease. Ann. Neurol. 52(5), 549-555 (2002).
111. Li YJ, Scott WK, Hedges DJ et al. Age at onset in two common neurodegenerative diseases is genetically controlled. Am. J. Hum. Genet. 70(4), 985-993 (2002).
112. Oliveira SA, Li YJ, Noureddine MA et al. Identification of risk and age-at-onset genes on chromosome 1p in Parkinson disease. Am. J. Hum. Genet. 77(2), 252-264 (2005).
113. Pankratz N, Nichols WC, Uniacke SK et al. Genome screen to identify susceptibility genes for Parkinson disease in a sample without parkin mutations. Am. J. Hum. Genet. 71(1), 124-135 (2002).
114. Strauss KM, Martins LM, Plun-Favreau H et al. Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Hum. Mol. Genet. 14(15), 2099-2111 (2005).
115. Tan EK, Khajavi M, Thornby JI et al. Variability and validity of polymorphism association studies in Parkinson's disease. Neurology 55(4), 533-538 (2000).
116. Jankovic J, Chen S, Le WD. The role of Nurr1 in the development of dopaminergic neurons and Parkinson's disease. Prog. Neurobiol. 77(1-2), 128-138 (2005).
117. Nichols WC, Uniacke SK, Pankratz N et al. Evaluation of the role of Nurr1 in a large sample of familial Parkinson's disease. Mov. Disord. 19(6), 649-655 (2004).
118. Healy DG, Abou-Sleiman PM, Ahmadi KR et al. NR4A2 genetic variation in sporadic Parkinson's disease: a genewide approach. Mov. Disord. 21(11), 1960-1963 (2006).
119. Engelender S, Kaminsky Z, Guo X et al. Synphilin-1 associates with α-synuclein and promotes the formation of cytosolic inclusions. Nat. Genet. 22(1), 110-114 (1999).
120. Marx FP, Soehn AS, Berg D et al. The proteasomal subunit S6 ATPase is a novel synphilin-1 interacting protein - implications for Parkinson's disease. FASEB J. 21(8), 1759-1767 (2007).
121. Mamah CE, Lesnick TG, Lincoln SJ et al. Interaction of α-synuclein and tau genotypes in Parkinson's disease. Ann. Neurol. 57(3), 439-443 (2005).
122. Healy DG, Abou-Sleiman PM, Lees AJ et al. Tau gene and Parkinson's disease: a case-control study and meta-analysis. J. Neurol. Neurosurg. Psychiatry 75(7), 962-965 (2004).
123. Zhang J, Song Y, Chen H, Fan D. The tau gene haplotype h1 confers a susceptibility to Parkinson's disease. Eur. Neurol. 53(1), 15-21 (2005).
124. Arima K, Hirai S, Sunohara N et al. Cellular co-localization of phosphorylated tau- and NACP/α-synuclein-epitopes in lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies. Brain Res. 843(1-2), 53-61 (1999).
125. Ishizawa T, Mattila P, Davies P, Wang D, Dickson DW. Colocalization of tau and α-synuclein epitopes in Lewy bodies. J. Neuropathol. Exp. Neurol. 62(4), 389-397 (2003).
126. Kwok JB, Teber ET, Loy C et al. Tau haplotypes regulate transcription and are associated with Parkinson's disease. Ann. Neurol. 55(3), 329-334 (2004).
127. Goker-Alpan O, Schiffmann R, LaMarca ME et al. Parkinsonism among Gaucher disease carriers. J. Med. Genet. 41(12), 937-940 (2004).
128. Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R. Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N. Engl. J. Med. 351(19), 1972-1977 (2004).
129. Hruska KS, Goker-Alpan O, Sidransky E. Gaucher disease and the synucleinopathies. J. Biomed. Biotechnol. 2006(3), 78549 (2006).
130. Clark LN, Haamer E, Mejia-Santana H et al. Construction and validation of a Parkinson's disease mutation genotyping array for the Parkin gene. Mov. Disord. 22(7), 932-937 (2007).
131. Mazzulli JR, Mishizen AJ, Giasson BI et al. Cytosolic catechols inhibit α-synuclein aggregation and facilitate the formation of intracellular soluble oligomeric intermediates. J. Neurosci. 26(39), 10068-10078 (2006).
132. Paleologou KE, Irvine GB, El-Agnaf OM. A-synuclein aggregation in neurodegenerative diseases and its inhibition as a potential therapeutic strategy. Biochem. Soc. Trans. 33(Pt 5), 1106-1110 (2005).
133. Emadi S, Barkhordarian H, Wang MS, Schulz P, Sierks MR. Isolation of a human single chain antibody fragment against oligomeric α-synuclein that inhibits aggregation and prevents α-synuclein-induced toxicity. J. Mol. Biol. 368(4), 1132-1144 (2007).
134. Perez-Tur J. Parkinson's disease genetics: a complex disease comes to the clinic. Lancet Neurol. 5(11), 896-897 (2006).
135. GeneTests www.geneclinics.org